Cyteir Therapeutics, a leader in the discovery and development of novel therapeutics based on the biology of DNA repair and synthetic lethality for the treatment of cancer and autoimmune diseases, announced the presentation of promising new preclinical data for the company's lead compound, CYT-0851.

Gemini Therapeutics, a product engine company focused on redefining dry AMD and linked disorders with precision medicine, today announced the initiation of CLARITY, a disease registry and natural history study designed to identify and characterize disease progression in subjects with non-central geographic atrophy (NC-GA) secondary to dry AMD, who are carriers of high-risk genetic variants. CLARITY will be used to inform and optimize the design of future interventional trials.

The Willow breast pump was one of the most talked about products at CES in 2017, since it was unlike any device of its kind. It's a wearable, quiet and hands free breast pump that fits inside your bra.
The company has just unveiled the Willow 2.0 at CES, which is an updated and improved version of its first pump.

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Tizona Therapeutics, Inc. ("Tizona"), a privately held immunotherapy company, announced today that they have entered into a global, strategic collaboration to develop and commercialize CD39-targeted therapeutics, including TTX-030, a first-in-class antibody for the treatment of cancer.